In this report, the global Stem Cell-Derived Cells market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025. Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Stem Cell-Derived Cells market during the forecast period (20XX-20XX)
ReNeuron, the UK based, clinical-stage stem cell therapeutics company, announced that new data relating to its CTX stem cell platform will be presented today at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT). Get a complete list of the presentations,here.
Share this Article You are free to share this article under the Attribution 4.0 International license.
Kyoto A project to make induced pluripotent stem cells, known as iPS cells, promptly and widely available at lower cost will get underway next year.
The pharmaceutical industry is one of the most scientifically innovative and competitive industries, particularly in oncology.
New light is being shed on a little-known role of Y chromosome genes, specific to males, that could explain why men suffer differently than women from various diseases, including COVID-19. The findings were published this month inScientific Reports by Universit de Montral (University of Montreal) professor Christian Deschepper, director of the Experimental Cardiovascular Biology research unit of the Montreal Clinical Research Institute.
NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in three key conferences in October 2020. The Jefferies Cell Therapy Virtual Summit will take place on October 5-6, 2020.Cytovia CEO Dr
News Release Monday, September 28, 2020 Findings show deficits in the electrical activity of cortical cells; possible targets for treatment for 22q11.2 deletion syndrome. A genetic study has identified neuronal abnormalities in the electrical activity of cortical cells derived from people with a rare genetic disorder called 22q11.2 deletion syndrome. The overexpression of a specific gene and exposure to several antipsychotic drugs helped restore normal cellular functioning
Key Developments in the Market: In March 2018, Kaneka Corporation announced that they have acquired a patent in the Japan for the creation of the method to mass-culture pluripotent stem cells including iPS cells and ES cells. This will help the company to use the technology to produce high quality pluripotent stem cells which can be used in the drug and cell therapy.
Stemson Therapeutics announced that it has raised a $7.5 million seed round of funding led by Allergan Aesthetics (an AbbVie Company) and impact investor Fortunis Capital to advance the development of Stemsons therapeutic solution to cure hair loss. This funding round enables Stemson to advance its goal of restoring human hair growth with a novel approach using the patients own cells to generate new hair follicles
Recent Comments